Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Bioregenx (BRGX) Change in Accured Expenses (2023 - 2025)

Bioregenx (BRGX) has 3 years of Change in Accured Expenses data on record, last reported at -$24896.0 in Q3 2025.

  • For Q3 2025, Change in Accured Expenses fell 187.54% year-over-year to -$24896.0; the TTM value through Sep 2025 reached -$34051.0, up 70.05%, while the annual FY2024 figure was $61583.0, 763.47% up from the prior year.
  • Change in Accured Expenses reached -$24896.0 in Q3 2025 per BRGX's latest filing, up from -$109036.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $94924.0 in Q2 2023 and bottomed at -$136984.0 in Q4 2023.
  • Average Change in Accured Expenses over 3 years is -$331.45, with a median of $28440.0 recorded in 2024.
  • The widest YoY moves for Change in Accured Expenses: up 251.04% in 2025, down 406.31% in 2025.
  • A 3-year view of Change in Accured Expenses shows it stood at -$136984.0 in 2023, then surged by 127.97% to $38310.0 in 2024, then plummeted by 164.99% to -$24896.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were -$24896.0 in Q3 2025, -$109036.0 in Q2 2025, and $61571.0 in Q1 2025.